...
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter.
【24h】

Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter.

机译:使用编码Na / I同向转运蛋白的Wnt靶向复制腺病毒进行靶向放射性核素治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The Na/I symporter (hNIS) promotes concentration of iodine in cells. In cancer gene therapy, this transgene has potential as a reporter gene for molecular imaging of viral biodistribution and as a therapeutic protein promoting (131)I-mediated radiotherapy. Here, we combined the imaging and therapeutic potential of hNIS in an oncolytic adenoviruses targeting colorectal cancer cells. EXPERIMENTAL DESIGN: We generated an adenovirus (AdIP2) encoding hNIS and capable of selective replication in colorectal carcinoma cells. The selectivity of this virus was verified in vitro and in vivo. Its spread in tumors was monitored in vivo using single-photon emission computed tomography/CT imaging upon (99m)TcO(4)(-) injection and confirmed by immunohistochemistry. Metabolic radiotherapy was done through injection of therapeutic doses of (131)I(-). RESULTS: We showed in vitro and in vivo the selectivity of AdIP2 and that hNIS expression is restricted to the target cells. Imaging and immunohistochemical data showed that viral spread is limited and that the point of maximal hNIS expression is reached 48 hours after a single intratumoral injection. Administration of a single therapeutic dose of (131)I at this time point led to a dramatic reduction in tumor size not observed in hNIS-negative viruses. CONCLUSIONS: This report showed for the first time that the combination of the imaging and therapeutic potentials of hNIS can be applied to oncolytic adenoviruses in experimental models of cancer.
机译:目的:Na / I同向转运蛋白(hNIS)促进细胞内碘的浓度。在癌症基因治疗中,该转基因作为病毒生物分布分子成像的报告基因和促进(131)I介导的放射治疗蛋白具有治疗潜力。在这里,我们结合了靶向结肠直肠癌细胞的溶瘤腺病毒中hNIS的成像和治疗潜力。实验设计:我们产生了编码hNIS并能够在结肠直肠癌细胞中选择性复制的腺病毒(AdIP2)。在体外和体内验证了该病毒的选择性。 (99m)TcO(4)(-)注射后,使用单光子发射计算机断层扫描/ CT成像在体内监测其在肿瘤中的扩散,并通过免疫组织化学确认。代谢放射疗法通过注射治疗剂量的(131)I(-)完成。结果:我们在体外和体内显示了AdIP2的选择性,并且hNIS的表达仅限于靶细胞。成像和免疫组化数据显示,病毒扩散受到限制,单次肿瘤内注射后48小时达到了最大hNIS表达点。在此时间点给予单一治疗剂量的(131)I导致hNIS阴性病毒中未观察到的肿瘤大小显着减少。结论:该报告首次表明,hNIS的成像和治疗潜力的组合可用于癌症实验模型中的溶瘤腺病毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号